Recursion Pharmaceuticals RXRX announced a significant investment worth $50 million from NVIDIA Corporation NVDA, a renowned technology company specializing in accelerated computing. This investment ...

Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across diverse ...

Recursion Pharmaceuticals, a drug discovery company that applies artificial intelligence to biology, is shoring up its technology platform by buying two startups that bolster its chemistry ...

Recursion hopes to transform the healthcare industry with its innovative drug discovery platform. The small company has gained the interest of Nvidia, which has invested in the business. Together, the ...

SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- The business combination of two AI-powered drug discovery and development companies, Recursion (Nasdaq: RXRX) and Exscientia has been completed, with ...

Recursion Pharmaceuticals is merging with Exscientia. The new entity will have the backing of quite a few big names in pharma. It'll also have an even more capable drug discovery and development ...

On sci-fi TV shows like Star Trek, when a doctor needs to cure a disease, they often ask the computer to simulate complex visualizations or go through databases for potential cures. In real life, ...

Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining of the AI biotech’s pipeline. Shrinking the Salt Lake City-based company’s ...

Recursion Pharmaceuticals RXRX shares have gained 5.5% in a month. The stock gained momentum after the company announced the acquisition of Rallybio’s full stake in their joint venture earlier this ...

We recently published 10 Best Biotech Stocks to Buy Under $10. Recursion Pharmaceuticals, Inc. is placed eighth among them. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a clinical-stage ...